Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212731 · ClinicalTrials.gov registry record
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 60
- Enrollment target
NCT01212731 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 60 participants.
The verdict
NCT01212731 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to: * estimate the degree of memory loss, if any following radiotherapy to the base of skull or brain as measured by standard neurocognitive battery testing. * describe radiotherapy dose-related changes in vascular perfusion, in spectroscopic parameters of neuronal injury and changes in the degree and directionality of tissue water diffusivity (diffusion tensor imaging) as a measure of white axonal injury. * to relate these imaging characteristics to the degree of memory loss.
Interventions
- RADIATION Photon treatment plans
- RADIATION Proton Treatment Plans
- BEHAVIORAL Neurocognitive evaluation
- DEVICE Advanced MRI imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-09 |
| Est. Completion | 2017-10-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01212731
The ClinicalTrials.gov registry entry for NCT01212731 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Photon treatment plans is the first listed.
NCT01212731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01212731 about?
NCT01212731 is a clinical study titled "Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study". The purpose of this study is to: * estimate the degree of memory loss, if any following radiotherapy to the base of skull or brain as measured by standard neurocognitive battery testing. * describe radiotherapy dose-related changes in vascular perfusion, in spectroscopic parameters of neuronal inju...
What is the current status of trial NCT01212731?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2010-09. Estimated completion is 2017-10-17.
What interventions are being tested in trial NCT01212731?
The interventions under investigation include: Photon treatment plans (RADIATION), Proton Treatment Plans (RADIATION), Neurocognitive evaluation (BEHAVIORAL), Advanced MRI imaging (DEVICE).
Who is sponsoring clinical trial NCT01212731?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.